MINYANVILLE ORIGINAL Highlighting their lead in a race to bring a new heart treatment to market Regeneron Pharmaceuticals (NASDAQ:REGN) and partner Sanofi (NYSE:SNY) said Monday that they are enrolling 18 000 patients in a late-stage clinical trial to further test an injected drug aimed at lowering bad cholesterol known as LDL. The drug part of a new class of medicines would treat people who can’t lower their LDL (low-density lipoprotein) cholesterol by taking widely used statin medicines like Pfizer’s (NYSE:PFE) Lipitor Merck’s (NYSE:MRK) Zocor or generic rivals. Regeneron and Sanofi are in a race with other companies including Amgen ...